Archive for January, 2022

Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium SOUTH SAN FRANCISCO, CA., January 31, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced…

Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases

Posted by amanda punzalan under Press (No Respond)

Business Wire Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases Clinical Trial Initiation of MZE001 for Pompe Disease Expected in First Half of 2022 Andy Tran…

Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Posted by amanda punzalan under Press (No Respond)

SOUTH SAN FRANCISCO, CA, January 5, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th…